O N C O L O G Y & H E M AT O L O G Y

E X P E R I E N C E

I N N O VAT I O N

Natural Hx of Disease

Subject Profiling

Rapid Online Feasibility

Site List Development

Investigator Identification

Country SelectionRecruit Rate Projections

Competitive LandscapeSite Volume Analysis

Pipeline Analysis

Investigator Grant Analysis

Leveraging SecondaryHealth Data for DecisionSupport in the Designand Execution of ClinicalResearch Studies

KOL Identification

Project Team Development

PRA leads the industry in advancing evidence-based approaches for the successful start-up and conduct of clinical trials. Leveraging evidence-based technology, we target the appropriate geographic areas for oncology disease prevalence and identify a targeted list of oncology/hematology investigators with the highest likelihood of accrual.

Approximately 60% of our medical directors have therapeutic expertise in oncology and hematology. In addition, a high percentage of our global project management and clinical operations team members are experienced in these indications, complementing their average of 10+ years of study conduct experience.

E X P E R T I S E

In greater than 60% of instances, our clients have adjusted their protocol design and/or country and site selection based on our evidence-based data and therapeu-tic experts’ recommendations.

MEDICAL DIRECTORS

=10%

CRAs PROJECT DIRECTORS AND MANAGERS

CLINICAL TEAM MANAGERS

60 80 85 90

WITH ONCOLOGY/HEMATOLOGY EXPERIENCE

O N C O L O G Y & H E M AT O L O G Y

As a recognized leader in conducting complex, global oncology/hematology trials, PRA has contributed to the approval of 12 important drugs. During the last 5 years, PRA has participated in more than 400 oncology and hematology clinical projects globally in every phase and virtually every indication, including supportive care.

OUR ONCOLOGYAND HEMATOLOGY EXPERTS MAKE THE COMPLEX, SIMPLE.

PRA worked on a drug that extended survival for breast cancer patients that was eventually FDA approved. This is what we are all about – in conjunction with our sponsors – delivering a be�er quality of life for patients.

PRA's global investigator network has enabled us to establish preferred access to investigative sites that are able to accrue patients and deliver high-quality clinical trial data.

We never forget that every global oncology/hematology study is executed locally. With global offices providing service in 80+ countries, our team harnesses practical knowledge of local regulations, standards of care and cultural customs to maximize safety and efficiency for your oncology trials.

“Our global footprint in traditional markets – as well as emerging markets – allows us to enroll patients rapidly in oncology trials. This enables us to bring our clients’ products to market in a cost-e�ective way while optimizing time and money during the drug development process.”

DR. UTE BERGER MDSr. Vice President, Medical Affairs

No OF CLINICAL SITES*

9,200+

No OF CLINICAL STUDIES*

400+

No OF APPROVED DRUGS

12

*OVER THE PAST 5 YEARS

No OF CLINICAL PATIENTS*

47,250+

PRA Health Sciences conducts comprehensive phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.

Our commitment to advance oncology clinical development is more than lip-service; today, we o�er our clients access to approximately 50 therapeutic experts in–house with experience in conducting oncology clinical trials.

To save lives, or enable people to live be�er lives, is no small thing. With every drug that we help bring to market, we not only improve the lives of the individuals who need it, but also all the lives that they touch. The ripples are countless, but the benefit is clear. With each and every trial, we’re working with our clients to change lives and to make the world a be�er place.

Our commitment to advance oncology/hematology clinical development is more than lip-service; today, we o�er our clients access to approximately 50 in–house therapeutic experts with experience in conducting oncology clinical trials.

To save lives, or enable people to live be�er lives, is no small thing. With every drug that we help bring to market, we not only improve the lives of the individuals who need it, but also all the lives that they touch. The ripples are countless, but the benefit is clear. With each and every trial, we’re working with our clients to change lives and to make the world a be�er place.

PRA Health Sciences conducts comprehensive Phase I-IV biopharmaceutical drug development. To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.